- Conditions
- Cervical Dystonia
- Interventions
- DaxibotulinumtoxinA for injection, Placebo
- Biological
- Lead sponsor
- Revance Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 496
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Propofol Injection Pain
- Interventions
- Passive arm elevation, Normal saline, Lidocaine, Propofol, Sham arm elevation
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Cocaine Use Disorder
- Interventions
- Semaglutide, Placebo, cognitive behavioral therapy (CBT).
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Osteoarthritis of the Knee
- Interventions
- TLC599, DSP, Normal Saline
- Drug · Other
- Lead sponsor
- Taiwan Liposome Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
- Interventions
- PVX4 Combination Product, Placebo Control
- Combination Product · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Postoperative Pain
- Interventions
- TLC590, Liposomal Bupivacaine, Saline Placebo
- Drug
- Lead sponsor
- TLC Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Bellaire, Texas • Houston, Texas + 1 more
- Conditions
- Dengue
- Interventions
- YF-17D, TDV, Placebo
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more
- Conditions
- Gastro Esophageal Reflux
- Interventions
- ARAT, Sham intervention (control)
- Procedure
- Lead sponsor
- Midwest Veterans' Biomedical Research Foundation
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Knee Osteoarthritis
- Interventions
- NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USP
- Drug
- Lead sponsor
- Nova Vita Laboratory
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chesterfield, Missouri
- Conditions
- Glabellar Frown Lines
- Interventions
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Biological · Other
- Lead sponsor
- Evolus, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Brow Ptosis, Facial Scarring
- Interventions
- 5-Fluorouracil, Normal Saline Flush, 0.9% Injectable Solution
- Drug
- Lead sponsor
- Eyelid and Facial Consultants
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Houma, Louisiana • New Orleans, Louisiana
- Conditions
- Eyelid Tumor, Eyelid Bump, Eyelid Deformity, Eyelid Abscess, Eyelid Boil, Eyelid Papilloma, Anesthesia, Local, Ophthalmology
- Interventions
- 0.9% Bacteriostatic Local Anesthetic Injection, 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection, Eyelid Lesion Removal
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Psoriasis
- Interventions
- Hylenex, Normal Saline
- Drug
- Lead sponsor
- Tissa Hata, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Familial Chylomicronemia
- Interventions
- Plozasiran, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 9
- States / cities
- Boca Raton, Florida • Suwanee, Georgia • Indianapolis, Indiana + 5 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab pegol (CZP), Placebo
- Drug · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,648 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more
- Conditions
- SARS-CoV-2 Infection
- Interventions
- 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- Biological · Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Injection Site Irritation, Injection Site Bruising, Injection Site Discomfort, Benzoic Acid Adverse Reaction, Anesthesia, Local
- Interventions
- Sodium Chloride 0.9% Inj, Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)
- Drug
- Lead sponsor
- Jeffrey Alan Klein, MD
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Juan Capistrano, California
- Conditions
- Systemic Lupus Erythematosus, Healthy
- Interventions
- JNJ-55920839, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina
- Conditions
- Healthy
- Interventions
- Saline, Glucagon, Placebo, Atenolol
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- High-Risk Melanoma
- Interventions
- gp100:209-217 (210M), Montanide ISA-51, Imiquimod
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 7 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Cancer, Prostate Cancer
- Interventions
- Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, 0.9% Sodium Chloride Injection
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Critical Illness, Depressive Symptoms
- Interventions
- Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
- Drug · Other
- Lead sponsor
- Hospital Italiano de Buenos Aires
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Multiple Sclerosis
- Interventions
- [18F] FZTA
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri